PRITELIVIR DEMONSTRATED SUPERIOR EFFICACY COMPARED TO INVESTIGATOR'S CHOICE TREATMENT FOR REFRACTORY HERPES SIMPLEX VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS: PRIOH-1, PHASE 3 SAFETY AND EFFICACY (EBMT 2026) - Feb 7, 2026 - Abstract #OS09-04; Pres time: Mar 24, 2026; 09:27 AM - 09:36 AM; Location: N104; P3 | " In this randomized (1:1), controlled, open label trial, 101 IC patients (≥16 years) with R±R HSV mucocutaneous infection received oral pritelivir (100 mg daily; 400 mg loading dose) or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod) for up to 28 days, extendable to 42 days. Eligibility criteria included hematopoietic cell transplant, solid organ transplant, HIV, malignancy, or chronic use of immunosuppressive treatment with refractory/clinical failure (defined as no clinical improvement of lesions after ≥7 days of standard of care nucleoside analogue therapy or confirmed acyclovir resistance)... Pritelivir met the Phase 3 primary endpoint, demonstrating statistically superior efficacy compared with ICT, with a favorable safety and tolerability profile. These findings support pritelivir as a promising oral agent to address the unmet needs of refractory HSV infections in IC patients.Table 1 Incidence of TEAEs (≥ 10%): Pritelivir vs...."
Clinical • P3 data • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Primary Immunodeficiency • Solid Organ Transplantation
|
|
Genovefa A. Papanicolaou1; Robin Avery2; Kimberly Workowski3; Karl S. Peggs4; Yeon Joo Lee1; Jean-Michel Molina5; Dionysios Neofytos6; Anum Abbas7; Alma Perez-Rios8; Jana Dickter9; Sanjeet Dadwal9; Stuart Cohen10; Nicolas Issa11; Palash Samanta12; Alexander Birkmann13; Cynthia Wat13; Dilruwan Chaminda Herath13; Alessandra Marini13; Bernadette Surujbally13; Melanie Sumner13; Anna Wald14; Roy Chemaly15
|